​***If you're a T2B member and do not receive your confirmation within 1 business day of RSVPing (above), check your email spam folder. The automated Luma email includes the cal invite.***

​T2Bmeet pricing:

• ​Complimentary for T2B Pro and Student community members (log into your T2B account and access your promo code here)

• ​$50 for Basic members

​If you're not part of Ticket to Biotech, confirm you're eligible, and join before registering for this event:

​T2B Intake Form

​Hosted by Alkermes and in partnership with Biosector 2, this come-and-go networking event is open to all biopharma communicators in the T2B community. Come mix and mingle with fellow comms pros!

​Program:

• ​4:30-5 p.m. – Check-in and networking

• ​5-5:45 p.m. – Panel discussion and Q&A

• ​5:45-7 p.m. – Reception and networking

​Complimentary snacks and drinks will be provided. ​See you there!

​New at the Q3 T2Bmeet @ Boston: Coaches Corner 

​Get focused support for a real workplace challenge in a 20-minute Power Coaching Session with leadership coaches Carly Goldsmith or Deb Becker. Both bring deep experience working with communications professionals and leaders in the biotech industry. Use your session to think through a decision, team dynamic, difficult conversation, or other pressing challenge and leave with greater clarity, confidence, and practical next steps. Sessions will be available during the event’s networking portions, with onsite sign-up when you arrive.

​Panel Discussion: Staying Relevant Between Milestones

​In biopharma, attention spikes around data readouts, regulatory decisions, financings, partnerships, and launches. We're the ones responsible for keeping a company's story alive in between, translating steady, unglamorous progress into something stakeholders can still follow. Yet staying visible between catalysts means walking a line: go too quiet and the narrative stalls, say too much and it starts to look manufactured. This panel opens a discussion on how communicators sustain narrative momentum between major catalysts, decide which interim stories are worth telling, and protect credibility for when it matters most.

​Key Takeaways:

• ​Tie individual announcements to a bigger enterprise narrative that can evolve through pipeline setbacks, leadership changes, and shifting timelines, while keeping the company's credibility intact.

• ​Sustain stakeholder confidence during long stretches when meaningful work is underway but headline results aren't.

• ​Identify which scientific, corporate, patient, leadership, and organizational stories meaningfully advance positioning, and who the right voice is to carry them.

• ​Protect visibility without manufacturing news, overstating the data, or setting expectations the business can't support.

​Meet Our Speakers

​Andrew Law, Senior Director, Global Business Communications, Blueprint Medicines

​Andrew Law brings more than 20 years of experience as a communications and public relations leader in the biopharmaceutical and life sciences industry. He is joining Sanofi following its acquisition of Blueprint Medicines, where he has held communications leadership roles since 2018. At Blueprint Medicines, Andrew spearheaded strategic portfolio communications from R&D programs to commercial medicines, and elevated visibility of the company as a fully integrated biopharmaceutical organization. In his corporate and portfolio communications roles, Andrew is responsible for translating Blueprint Medicines’ focus areas into accessible information that resonates with a diverse set of external stakeholders. Previously, Andrew held life sciences communications roles at Biogen and MSLGroup, a global PR agency owned by the Public Groupe. In 2002, he graduated from Haverford College with a B.S. degree in Chemistry.

​Gretchen Murphy, Senior Director, Corporate and R&D Communications and Patient Advocacy, Alkermes

​Gretchen Murphy is Senior Director of Corporate and R&D Communications and Patient Advocacy at Alkermes, where she leads communications strategies that advance understanding of the company’s neuroscience portfolio. She is dedicated to ensuring patient experiences inform how the company listens, learns and communicates across its research and development efforts.

​Prior to joining Alkermes in 2017, she held communications roles at Medidata and Chandler Chicco Companies. Gretchen holds a B.S. in Communications from Cornell University and an M.S. in Public Relations from Syracuse University’s S.I. Newhouse School of Public Communications.

​Carlo Tanzi, Ph.D., Founder and Principal, Kendall Investor Relations

​Carlo Tanzi, Ph.D., is Founder and Principal of Kendall Investor Relations, a biotech-focused firm advising private and public companies on investor strategy, positioning, and execution across financings. He founded the firm in 2018.

​Before founding Kendall IR, Carlo was Vice President of Investor Relations and Corporate Communications at Seres Therapeutics, where he served on the leadership team. Earlier, he spent nine years at Biogen in investor relations and program management roles, including Director of Investor Relations and Program Management Lead for Tecfidera and Tysabri. He began his career as a healthcare management consultant at Health Advances.

​His IR experience spans multiple product launches, IPO and follow-on financings, clinical data readouts, R&D investor days, sell-side engagement, and investor targeting. He holds a Ph.D. in molecular biology from the University of Pennsylvania.

​Alina Worth, Managing Director, Biosector 2

​Alina is an experienced leader with a demonstrated history of merging complex science with fresh ideas within the bounds of healthcare compliance. Through her partnerships with leading pharmaceutical companies to small and midsize biotechs she has tackled scientific brand communications challenges across the product life cycle. From first-of-its-kind data to late-market entry and product maturation, Alina is masterful at narrating and visually showcasing a powerful story.

​Lynnea Olivarez, Founder, Ticket to Biotech (Moderator)

​Lynnea Olivarez founded the global biopharma communicator community Ticket to Biotech (T2B) after 15 years driving corporate affairs initiatives across the drug development lifecycle. Since its 2023 launch, T2B has attracted hundreds of communications practitioners to elevate the profession’s influence and deepen impact across the life sciences.

​Lynnea has guided integrated communications strategies for dozens of organizations spanning industry, agency, and government. She most recently managed corporate communications as a VP at gene therapy company Encoded Therapeutics. Before that, Lynnea was recognized in PR News as a 2020 Top Woman in PR for her work at Intellia Therapeutics helping initiate a clinical trial investigating the first CRISPR therapy to edit genes inside the human body. Previously supporting the pivotal study readouts, launch, and pricing of the first gene therapy for a genetic disease is another career highlight.

​Lynnea also has advised a spectrum of life science clients at boutique PR firms, spearheaded mar-comm for the Massachusetts Life Sciences Center, and led global IT communications at Novartis Biomedical Research. A summa cum laude Northeastern University graduate, she chairs the American Society of Gene and Cell Therapy Communications Committee, serves on Life Science Cares’ National Board of Advisors, and is a past president of the Public Relations Society of America SF Bay Area Chapter (2024).

​About Our Host, Alkermes, Inc.

​Alkermes applies its decades of deep neuroscience expertise to develop medicines designed to help people living with complex, chronic psychiatric and neurological disorders. A global biopharmaceutical company headquartered in Dublin, Ireland, with U.S. locations in Massachusetts and Ohio, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of important new medicines in areas which are often overlooked, including addiction, serious mental illness and sleep disorders. Visit www.alkermes.com to learn more.

​

​About Our Event Partner, Biosector 2

​Biosector 2 is built around a model that prioritizes senior expertise and long-term relationships in healthcare communications. Part of Syneos Health, the agency operates exclusively in healthcare and life sciences, working with companies navigating high-stakes moments where scientific, regulatory and reputational pressures intersect. Rather than scaling through volume, it has leaned into depth — embedding senior advisors directly into client work.

​That approach is reflected in its structure. The agency’s “Brain Bank” model gives teams rapid access to specialized expertise across the firm, often delivering coordinated guidance within hours on complex issues.

​Growth has followed from those relationships. More than two-thirds of 2025 growth came from existing clients through expanded scopes and new assignments, with more than half of clients remaining on the roster for three years or longer.

​The work focuses on translating complex science into communications that resonate across audiences. Recent programs include campaigns raising awareness of RSV protection among parents through trusted voices and community engagement, as well as storytelling initiatives centered on lived experiences within rare disease communities.

​That emphasis on connection extends internally. The agency’s culture is built around mentorship and knowledge-sharing, with long-tenured leadership and structured programs linking senior advisors with emerging talent. Leadership tenure averages more than 15 years.  The result is a firm that has chosen to deepen expertise and relationships in a sector where both are critical to navigating uncertainty.